Real-World Eligibility for Second-Line Chimeric Antigen Receptor T Cell Therapy in Large B Cell Lymphoma: A Population-Based Analysis
Authors:
Open Access
- 2 February 2022
- journal article
- research article
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 28 (4) , 218.e1-218.e4
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell LymphomaNew England Journal of Medicine, 2022
- CAR T-cell therapy for secondary CNS DLBCLBlood Advances, 2021
- Real-World Outcomes of Axicabtagene Ciloleucel (Axi-cel) for the Treatment of Large B-Cell Lymphoma (LBCL): Impact of Age and Specific Organ DysfunctionBlood, 2021
- Lisocabtagene Maraleucel (liso-cel), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy, Versus Standard of Care (SOC) with Salvage Chemotherapy (CT) Followed By Autologous Stem Cell Transplantation (ASCT) As Second-Line (2L) Treatment in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Randomized Phase 3 Transform StudyBlood, 2021
- Clinical activity of axicabtagene ciloleucel in adult patients with Richter syndromeBlood Advances, 2020
- Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphomaBlood, 2020
- Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T ConsortiumJournal of Clinical Oncology, 2020
- Relapsed/Refractory Diffuse Large B-Cell LymphomaHematology-American Society Hematology Education Program, 2011
- Autologous Bone Marrow Transplantation as Compared with Salvage Chemotherapy in Relapses of Chemotherapy-Sensitive Non-Hodgkin's LymphomaNew England Journal of Medicine, 1995